TriSalus Life Sciences (TLSI)
NASDAQ:TLSI
Want to see TLSI full AI Analyst Report?
TLSI Stock Chart & Stats
$4.65
-$0.05(-0.97%)
At close: 4:00 PM EST
$4.65
-$0.05(-0.97%)
Day’s Range― - ―
52-Week Range$2.20 - $7.95
Previous CloseN/A
Volume4.84K
Average Volume (3M)227.57K
Market Cap
$204.82M
Enterprise Value$107.21M
Total Cash (Recent Filing)$56.55M
Total Debt (Recent Filing)$34.49M
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 19, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding61,416,534
10 Day Avg. Volume200,051
30 Day Avg. Volume227,568
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)-7.81
Price to Sales (P/S)5.86
P/FCF Ratio-13.97
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue2.39
Enterprise Value/Gross Profit2.81
Enterprise Value/Ebitda-3.32
Forecast
1Y Price Target
$8.80Price Target Upside89.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$53.67M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained mid-80s gross margins indicate strong unit economics for TriNav consumables and procedures. Durable margin strength supports reinvestment in R&D and commercialization, buffers operating losses, and reflects potential pricing power and manufacturing scale advantages over time.
Robust Real‑world Clinical EvidenceA large, multi-payer real-world study showing fewer complications, more drug delivery and ~$7.7k downstream cost avoidance builds durable clinical and economic credibility. This evidence aids payer discussions, physician adoption, and competitive differentiation across indications.
Commercial Build And Leadership AdditionsDoubling the salesforce and hiring senior commercial leadership reflects a deliberate, funded go-to-market strategy. With a defined 6–9 month rep ramp and added clinical leadership, the company is positioning for scalable, multi-year adoption across key territories and new indications.
Bears Say
Sharp Revenue DeclineA near-60% TTM revenue drop signals structural demand or execution gaps and creates operating leverage stress. Lower revenue undermines the company's ability to absorb fixed costs, extend clinical programs, and sustain the commercial expansion without clear sequential recovery.
Persistent Cash BurnConsistent negative OCF and FCF (~$20M TTM) mean ongoing reliance on external financing. This persistent burn constrains strategic optionality, risks dilution or costly capital raises, and limits runway for clinical trials and sales investments absent sustained revenue improvement.
Elevated Leverage And Constrained Balance SheetMaterial debt growth and a high debt-to-equity ratio reduce financial flexibility while operating losses persist. Elevated leverage increases refinancing and interest risks, limiting the company's capacity to fund trials, commercial scale-up, or withstand further revenue setbacks.
TriSalus Life Sciences News
TLSI FAQ
What was TriSalus Life Sciences’s price range in the past 12 months?
TriSalus Life Sciences lowest stock price was $2.20 and its highest was $7.95 in the past 12 months.
What is TriSalus Life Sciences’s market cap?
TriSalus Life Sciences’s market cap is $204.82M.
When is TriSalus Life Sciences’s upcoming earnings report date?
TriSalus Life Sciences’s upcoming earnings report date is Aug 19, 2026 which is in 76 days.
How were TriSalus Life Sciences’s earnings last quarter?
TriSalus Life Sciences released its earnings results on May 12, 2026. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.188.
Is TriSalus Life Sciences overvalued?
According to Wall Street analysts TriSalus Life Sciences’s price is currently Undervalued.
Does TriSalus Life Sciences pay dividends?
TriSalus Life Sciences does not currently pay dividends.
What is TriSalus Life Sciences’s EPS estimate?
TriSalus Life Sciences’s EPS estimate is -0.15.
How many shares outstanding does TriSalus Life Sciences have?
TriSalus Life Sciences has 61,416,534 shares outstanding.
What happened to TriSalus Life Sciences’s price movement after its last earnings report?
TriSalus Life Sciences reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -41.447%.
Which hedge fund is a major shareholder of TriSalus Life Sciences?
Currently, no hedge funds are holding shares in TLSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TriSalus Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.80 (89.25% Upside)
$8.80 (89.25% Upside)
Blogger Sentiment
Bullish
TLSI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 109.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.00%
12-Months-Change
Fundamentals
Return on Equity
162.57%
Trailing 12-Months
Asset Growth
147.96%
Trailing 12-Months
Company Description
TriSalus Life Sciences
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
TLSI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a major clinical and economic validation of PEDD (landmark real-world study, strong pipeline, meaningful early results in multiple new indications) and a deliberate commercial build intended to capture a large addressable market. Near-term financials were impacted by the deliberate salesforce expansion (temporary revenue disruption, higher operating losses) and a regulatory delay for TriNav Advance that defers some expected second-half revenue. Management positions the investments as strategic and funded by a solid cash balance, with expectations of sustained ramp and commercial momentum through the remainder of 2026 and beyond.View all TLSI earnings summariesTLSI Stock 12 Month Forecast
Average Price Target
$8.80
▲(89.25% Upside)
Technical Analysis
Ownership Overview
29.58% Insiders
6.66% Mutual Funds
22.90% Other Institutional Investors
36.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---